$ARDX
ARDELYX, INC. Stock $ardx

$ardx Overview Financials Valuation SEC Filings Company Website

2017 Q2 Form 10-Q Financial Statement

#000119312517159933 Filed on May 05, 2017

Income Statement

Concept	2017 Q2	2017 Q1	2016 Q1
Revenue	$0.00	$0.00	$0.00
YoY Change			-100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$5.850M	$6.050M	$4.280M
YoY Change	20.62%	41.36%	34.59%
% of Gross Profit
Research & Development	$20.57M	$22.39M	$19.25M
YoY Change	-13.7%	16.3%	210.58%
% of Gross Profit
Depreciation & Amortization	$650.0K	$594.0K	$310.0K
YoY Change	103.13%	91.61%	160.5%
% of Gross Profit
Operating Expenses	$26.42M	$28.43M	$23.53M
YoY Change	-7.92%	20.85%	151.03%
Operating Profit	-$26.42M	-$28.43M	-$23.53M
YoY Change	-7.92%	20.85%	574.18%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	$697.0K	$426.0K	$62.00K
YoY Change	805.19%	587.1%	-616.67%
Pretax Income	-$25.72M	-$28.01M	-$23.47M
YoY Change	-10.11%	19.35%	570.1%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$25.72M	-$28.01M	-$23.47M
YoY Change	-10.11%	19.35%	570.1%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$542.6K	-$591.7K	-$701.2K
COMMON SHARES
Basic Shares Outstanding	47.39M shares	47.33M shares	34.63M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q2	2017 Q1	2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$148.7M	$173.4M	$171.7M
YoY Change	1.38%	1.0%	74.67%
Cash & Equivalents	$63.64M	$71.21M	$171.7M
Short-Term Investments	$85.09M	$102.2M
Other Short-Term Assets	$5.200M	$4.600M	$4.000M
YoY Change	40.54%	15.0%	166.67%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$153.9M	$178.0M	$175.7M
YoY Change	2.35%	1.32%	72.41%
LONG-TERM ASSETS
Property, Plant & Equipment	$9.335M	$8.915M	$4.597M
YoY Change	93.39%	93.93%	39.77%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$842.0K	$842.0K	$104.0K
YoY Change	468.92%	709.62%	0.0%
Total Long-Term Assets	$10.18M	$9.757M	$4.801M
YoY Change	104.56%	103.23%	37.45%
TOTAL ASSETS
Total Short-Term Assets	$153.9M	$178.0M	$175.7M
Total Long-Term Assets	$10.18M	$9.757M	$4.801M
Total Assets	$164.1M	$187.8M	$180.5M
YoY Change	5.63%	4.03%	71.25%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.713M	$5.893M	$4.875M
YoY Change	-0.7%	20.88%	91.63%
Accrued Expenses	$12.80M	$12.80M	$4.100M
YoY Change	50.59%	212.2%	192.86%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$18.39M	$19.31M	$12.46M
YoY Change	30.77%	55.03%	-37.43%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$756.0K	$767.0K	$292.0K
YoY Change	6.03%	162.67%	-1.68%
Total Long-Term Liabilities	$756.0K	$767.0K	$292.0K
YoY Change	6.03%	162.67%	-1.68%
TOTAL LIABILITIES
Total Short-Term Liabilities	$18.39M	$19.31M	$12.46M
Total Long-Term Liabilities	$756.0K	$767.0K	$292.0K
Total Liabilities	$19.14M	$20.08M	$12.75M
YoY Change	29.58%	57.5%	-73.1%
SHAREHOLDERS EQUITY
Retained Earnings	-$267.6M	-$241.9M	-$125.0M
YoY Change	74.26%	93.58%	65.79%
Common Stock	$412.6M	$409.6M	$292.7M
YoY Change	40.26%	39.94%	119.47%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$145.0M	$167.7M	$167.7M
YoY Change
Total Liabilities & Shareholders Equity	$164.1M	$187.8M	$180.5M
YoY Change	5.63%	4.03%	71.25%

Cashflow Statement

Concept	2017 Q2	2017 Q1	2016 Q1
OPERATING ACTIVITIES
Net Income	-$25.72M	-$28.01M	-$23.47M
YoY Change	-10.11%	19.35%	570.1%
Depreciation, Depletion And Amortization	$650.0K	$594.0K	$310.0K
YoY Change	103.13%	91.61%	160.5%
Cash From Operating Activities	-$23.89M	-$26.76M	-$16.25M
YoY Change	-4.06%	64.68%	97.93%
INVESTING ACTIVITIES
Capital Expenditures	-$790.0K	$1.118M	$200.0K
YoY Change	163.33%	459.0%	-81.04%
Acquisitions
YoY Change
Other Investing Activities	$17.08M	$24.09M
YoY Change
Cash From Investing Activities	$16.29M	$22.97M	-$200.0K
YoY Change	-5530.0%	-11585.0%	-81.13%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$80.84M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	10.00K	410.0K	81.12M
YoY Change	-94.74%	-99.49%	26940.0%
NET CHANGE
Cash From Operating Activities	-23.89M	-26.76M	-16.25M
Cash From Investing Activities	16.29M	22.97M	-200.0K
Cash From Financing Activities	10.00K	410.0K	81.12M
Net Change In Cash	-7.590M	-3.380M	64.67M
YoY Change	-69.65%	-105.23%	-820.96%
FREE CASH FLOW
Cash From Operating Activities	-$23.89M	-$26.76M	-$16.25M
Capital Expenditures	-$790.0K	$1.118M	$200.0K
Free Cash Flow	-$23.10M	-$27.88M	-$16.45M
YoY Change	-6.1%	69.47%	77.55%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	47386756	shares
CY2015Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.125
CY2015Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	2172899	shares
CY2015Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	10.70
CY2016Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	171678000
CY2017Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1856000
CY2017Q1	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	71213000
CY2017Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2017Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	53000
CY2017Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	173471000
CY2017Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2017Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	47386756	shares
CY2017Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	47386756	shares
CY2017Q1	us-gaap	Assets Assets	187765000
CY2017Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	5000
CY2017Q1	us-gaap	Assets Current AssetsCurrent	178008000
CY2017Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2017Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	409610000
CY2017Q1	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	102258000
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	71213000
CY2017Q1	us-gaap	Common Stock Value CommonStockValue	5000
CY2017Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	5893000
CY2017Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	102210000
CY2017Q1	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0
CY2017Q1	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0
CY2017Q1	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	11565000
CY2017Q1	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	0
CY2017Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-48000
CY2017Q1	us-gaap	Available For Sale Securities AvailableForSaleSecurities	102210000
CY2017Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2017Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2017Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	647000
CY2017Q1	us-gaap	Liabilities Liabilities	20081000
CY2017Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	187765000
CY2017Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	767000
CY2017Q1	us-gaap	Liabilities Current LiabilitiesCurrent	19314000
CY2017Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	842000
CY2017Q1	us-gaap	Preferred Stock Value PreferredStockValue
CY2017Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8915000
CY2017Q1	us-gaap	Stockholders Equity StockholdersEquity	167684000
CY2017Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-241883000
CY2017Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4585000
CY2017Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q1	ardx	Cash And Cash Equivalents Gross Unrealized Gains CashAndCashEquivalentsGrossUnrealizedGains	0
CY2017Q1	ardx	Cash Cash Equivalents And Short Term Investments Gross Unrealized Losses CashCashEquivalentsAndShortTermInvestmentsGrossUnrealizedLosses	53000
CY2017Q1	ardx	Cash Cash Equivalents And Short Term Investments Fair Value Disclosure CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure	173423000
CY2017Q1	ardx	Cash And Cash Equivalents Gross Unrealized Losses CashAndCashEquivalentsGrossUnrealizedLosses	0
CY2017Q1	ardx	Accrued Clinical Trial Expenses AccruedClinicalTrialExpenses	7517000
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5635000
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	78000
CY2017Q1	ardx	Cash Cash Equivalents And Short Term Investments Gross Unrealized Gains CashCashEquivalentsAndShortTermInvestmentsGrossUnrealizedGains	5000
CY2017Q1	ardx	Accrued Contract Manufacturing Costs AccruedContractManufacturingCosts	3010000
CY2017Q1	ardx	Accrued Professional And Consultant Fees Current AccruedProfessionalAndConsultantFeesCurrent	391000
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	107004000
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3161000
CY2016Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	74598000
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2016Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	200894000
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	47309422	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	47309422	shares
CY2016Q4	us-gaap	Assets Assets	213131000
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	7000
CY2016Q4	us-gaap	Assets Current AssetsCurrent	203992000
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2016Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	407092000
CY2016Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	126296000
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	74598000
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	5000
CY2016Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	126225000
CY2016Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	10405000
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-71000
CY2016Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	126225000
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	684000
CY2016Q4	us-gaap	Liabilities Liabilities	19980000
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	213131000
CY2016Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	779000
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	19201000
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	148000
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8991000
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	193151000
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-213875000
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3169000
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	ardx	Cash And Cash Equivalents Gross Unrealized Gains CashAndCashEquivalentsGrossUnrealizedGains	0
CY2016Q4	ardx	Cash Cash Equivalents And Short Term Investments Gross Unrealized Losses CashCashEquivalentsAndShortTermInvestmentsGrossUnrealizedLosses	78000
CY2016Q4	ardx	Cash Cash Equivalents And Short Term Investments Fair Value Disclosure CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure	200823000
CY2015Q2	invest	Investment Warrants Exercise Price InvestmentWarrantsExercisePrice	13.91
CY2015Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	74300000
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.59
CY2017Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2109000
CY2017Q1	us-gaap	Cost Of Services Amortization CostOfServicesAmortization	46000
CY2016Q4	ardx	Cash And Cash Equivalents Gross Unrealized Losses CashAndCashEquivalentsGrossUnrealizedLosses	0
CY2016Q4	ardx	Accrued Clinical Trial Expenses AccruedClinicalTrialExpenses	6694000
CY2016Q4	ardx	Cash Cash Equivalents And Short Term Investments Gross Unrealized Gains CashCashEquivalentsAndShortTermInvestmentsGrossUnrealizedGains	7000
CY2016Q4	ardx	Accrued Contract Manufacturing Costs AccruedContractManufacturingCosts	2705000
CY2016Q4	ardx	Accrued Professional And Consultant Fees Current AccruedProfessionalAndConsultantFeesCurrent	322000
CY2015Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	7242992	shares
CY2015Q2	ardx	Gross Proceeds From Issuance Of Common Stock GrossProceedsFromIssuanceOfCommonStock	77800000
CY2017Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	48000
CY2017Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	72000
CY2017Q1	dei	Entity Registrant Name EntityRegistrantName	Ardelyx, Inc.
CY2017Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6100000	shares
CY2017Q1	dei	Document Type DocumentType	10-Q
CY2017Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001437402
CY2017Q1	dei	Document Period End Date DocumentPeriodEndDate	2017-03-31
CY2017Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-3385000
CY2017Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
CY2017Q1	dei	Amendment Flag AmendmentFlag	false
CY2017Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2017Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6047000
CY2017Q1	us-gaap	Depreciation Depreciation	594000
CY2017Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-27985000
CY2017Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2017Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	408000
CY2017Q1	us-gaap	Operating Expenses OperatingExpenses	28434000
CY2017Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2017Q1	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	1149000
CY2017Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	426000
CY2017Q1	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	10482000
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-28008000
CY2017Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-28008000
CY2017Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	22968000
CY2017Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	23000
CY2017Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	31872000
CY2017Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	858000
CY2017Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2228000
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-28434000
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	408000
CY2017Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	18268000
CY2017Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-1305000
CY2017Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-26761000
CY2017Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1118000
CY2017Q1	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> <b><i>Use of Estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Although management believes these estimates are based upon reasonable assumptions within the bounds of its knowledge of the Company’s business and operations, actual results could differ materially from those estimates.</p> </div>
CY2017Q1	dei	Trading Symbol TradingSymbol	ARDX
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	22387000
CY2017Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2109000
CY2017Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	47343234	shares
CY2017Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	Segment
CY2017Q1	ardx	Class Of Warrant Or Right Expiration Date Description ClassOfWarrantOrRightExpirationDateDescription	The warrants are exercisable for an exercise price of $13.91 per share.
CY2017Q1	ardx	Class Of Warrant Or Right Number Of Warrants Exercised ClassOfWarrantOrRightNumberOfWarrantsExercised	0	shares
CY2016Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	80000
CY2016Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4500000	shares
CY2016Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	64674000
CY2016Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.70
CY2016Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1191000
CY2016Q1	us-gaap	Cost Of Services Amortization CostOfServicesAmortization	47000
CY2016Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4279000
CY2016Q1	us-gaap	Depreciation Depreciation	310000
CY2016Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-23467000
CY2016Q1	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	3656000
CY2016Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	62000
CY2016Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	284000
CY2016Q1	us-gaap	Operating Expenses OperatingExpenses	23529000
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-23467000
CY2016Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-23467000
CY2016Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-200000
CY2016Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2102000
CY2016Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-881000
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-23529000
CY2016Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	81121000
CY2016Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-1047000
CY2016Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2016Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-16247000
CY2016Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	200000
CY2016Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	80837000
CY2016Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19250000
CY2016Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1191000
CY2016Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	33466955	shares

Files In Submission

Name	View Source	Status
0001193125-17-159933-index-headers.html	Edgar Link	pending
0001193125-17-159933-index.html	Edgar Link	pending
0001193125-17-159933.txt	Edgar Link	pending
0001193125-17-159933-xbrl.zip	Edgar Link	pending
ardx-20170331.xml	Edgar Link	completed
ardx-20170331.xsd	Edgar Link	pending
ardx-20170331_cal.xml	Edgar Link	unprocessable
ardx-20170331_def.xml	Edgar Link	unprocessable
ardx-20170331_lab.xml	Edgar Link	unprocessable
ardx-20170331_pre.xml	Edgar Link	unprocessable
d384007d10q.htm	Edgar Link	pending
d384007dex311.htm	Edgar Link	pending
d384007dex312.htm	Edgar Link	pending
d384007dex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ARDX
ARDELYX, INC. Stock $ardx

2017 Q2 Form 10-Q Financial Statement

#000119312517159933 Filed on May 05, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ARDX ARDELYX, INC. Stock $ardx

2017 Q2 Form 10-Q Financial Statement

#000119312517159933 Filed on May 05, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ARDX
ARDELYX, INC. Stock $ardx